Anti-VEGF Antibodies Markets 2017-2022: Global Technology Assessment, Market Analysis and Future Growth Trends Report 2018 - ResearchAndMarkets.com
Aug. 09, 2018
DUBLIN--(BUSINESS WIRE)--Aug 9, 2018--The "Anti-VEGF Antibodies: Global Technology Assessment, Market Analysis and Future Growth Trends" report has been added to ResearchAndMarkets.com's offering.
Due to rapid advancements in genetic sequencing and the translation of basic medical sciences research into clinical practice, humanized mAbs have turnout to be fastest growing group of biotechnology-derived molecules in clinical trials. Driven by the growing application area pertaining to target disease viz. cancers, autoimmune disorders, infectious diseases, the monoclonal antibody market was valued over US$ 100 billion in 2017 and is forecast to grow at a double digit Compound Annual Growth Rate (CAGR) by year 2023.
Although various small molecule kinase inhibitors have been approved for targeting VEGF induced signaling, but the use of mAbs against VEGF have been established since FDA approval of Bevacizumab (Avastin, Genentech/Roche) in year 2004. Since, Avastin, FDA has approved ranibizumab (Lucentis, Genentech/Roche) and aflibercept (Eylea, Regeneron Pharma) both for cancer treatment and age related macular degradation (AMD). Therefore, use of mAbs in targeting VEGF induced angiogenesis in cancer, inflammation, arthritis and AMDs have tremendous potential in near future.
The report includes following key insights:In this report we discuss the novel technologies/methodologies used for production, purification, structural modifications and formulation of mAbs against VEGF ligands in various human pathologies using technology distribution based on IP analysis The report highlights the significant trends in efficacy, limitations and patient survival rate anti-VEGF antibodies therapy based on data available for Avastin, Lucentis, Eylea, Vanucizumab, Brolucizumab and hPV19 This report showcases the competitive benchmarking of key industrial players like Roche, Sanofi, Novartis, Regeneron Pharma, AbbVie etc. in development of anti-VEGF antibodies from laboratory to clinical trials Product search and market forecast for trends in anti-VEGF mAbs will be extensively described The report will further include detailed description of anti-VEGF antibodies in clinical trials and their beneficial effects on targeted patients especially cancer and age related macular degradation, autoimmune diseases Report includes driving factors influencing global anti-VEGF mAbs market for year 2017-2022 Detailed description of SWOT and PEST analysis in development of anti-VEGF antibody therapy.
Key industry playersRoche Novartis Sanofi Regeneron Bayer AstraZeneca
Key Topics Covered:
1. Technology Overview
2. Anti-VEGF antibodies: Technology Segmentation
3. Anti-VEGF antibodies: Global IP Trends
4. Anti-VEGF antibodies: Different diseases targeted
5. Anti-VEGF antibody: White Space Analysis
6. Recent activities in development of anti-VEGF antibody
7. Anti-VEGF Antibody Technology Opinions from Experts
8. Anti-VEGF Antibody Technology Collaboration Insights
9. Strategies of Companies involved in development of Anti-VEGF antibody
10. Recent Anti-VEGF Antibody Product Developments
11. Global Trends Anti-VEGF Antibody Market
12. Global Anti-VEGF antibody development: Top Industrial Players
13. Anti-VEGF Antibody - Market Determinants
14. Anti-VEGF Antibody -Opportunity Vs. Restraints
15. Anti-VEGF Antibody: Strategic Analysis SWOT & PEST
16. Anti-VEGF Antibody Market Development (2017-2022)
For more information about this report visit https://www.researchandmarkets.com/research/wkb849/antivegf?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180809005346/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Biotechnology,Immune Disorders Drugs
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/09/2018 07:26 AM/DISC: 08/09/2018 07:26 AM